Furthermore, the combination of Capecitabine (a prodrug that is converted to 5-FU by thymidine phosphorylase) and Celecoxib (a Cox-2 inhibitor) reduced the number of mice with pancreatic adenocarcinoma, which was associated with a recovery of SOD and CAT activity (56). The gene discussed is CAT; the disease is pancreatic adenocarcinoma.